ALKS stock icon

Alkermes
ALKS

$24.5
1.25%
 

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 2,100

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

93% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 29

14% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $12M

9% more funds holding

Funds holding: 299 [Q4 2023] → 326 (+27) [Q1 2024]

3% less capital invested

Capital invested by funds: $4.87B [Q4 2023] → $4.7B (-$168M) [Q1 2024]

7% less repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 118

1.17% less ownership

Funds ownership: 105.14% [Q4 2023] → 103.97% (-1.17%) [Q1 2024]

100% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 0 (-4) [Q1 2024]

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$25
2%
upside
Avg. target
$37
52%
upside
High target
$50
104%
upside

10 analyst ratings

positive
50%
neutral
40%
negative
10%
HC Wainwright & Co.
Douglas Tsao
43%upside
$35
Neutral
Reiterated
4 Jun 2024
Cantor Fitzgerald
Charles Duncan
96%upside
$48
Overweight
Maintained
23 May 2024
HC Wainwright & Co.
Douglas Tsao
43%upside
$35
Neutral
Reiterated
2 May 2024
HC Wainwright & Co.
Douglas Tsao
43%upside
$35
Neutral
Reiterated
19 Apr 2024
Jefferies
Akash Tewari
104%upside
$50
Buy
Maintained
9 Apr 2024

Financial journalist opinion

Based on 6 articles about ALKS published over the past 30 days